It wasn't that long ago that Intuitive Surgical (NASDAQ: ISRG) was dealing with pandemic-related issues. The company's procedure volume dropped noticeably with the outbreak, leading to lower-than-expected revenue and earnings.

Intuitive did bounce back, much to the joy of investors. However, the medical device specialist is now dealing with a completely different issue harming its financial results. During the company's second-quarter earnings conference call, management had something to say about this issue. Let's look deeper.

Intuitive Surgical is best known for the da Vinci system, a robotic-assisted surgery (RAS) device that allows physicians to perform various procedures, from kidney removals to hernia repairs. One category of procedures conducted with this device is now attracting a lot of attention: bariatric surgeries. Some analysts predicted that the rise in popularity of GLP-1 medicines like Wegovy and Zepbound would lead to a decline in demand for weight loss procedures.

Continue reading

Source Fool.com